Specialized Therapies | HIV and Oncology
Press Releases and Company Announcements
Theratechnologies Receives FDA Agreement to Amended Trial Protocol for its Lead PDC Candidate Sudocetaxel Zendusortide
Theratechnologies to Present Preliminary Safety and Efficacy Data from Phase 1 Trial of Sudocetaxel Zendusortide in Heavily Pretreated Cancer Patients at ASCO 2023
Theratechnologies’ Trogarzo® (Ibalizumab-uiyk) Shortens Time to HIV Undetectability and Extends Durability of Undetectability and Viral Suppression in a Matched Treatment Comparison
Pipeline & Medicines
Product Pipeline & Portfolio
Theratechnologies develops and commercializes innovative therapies. The Company currently commercializes two products in the field of HIV. Trogarzo® and EGRIFTA SV® are approved in the United States. We have a Phase 1 clinical trial in oncology using our novel and proprietary SORT1+ Technology™. We also plan to initiate a Phase 3 clinical trial to evaluate tesamorelin as a potential treatment for nonalcoholic steatohepatitis (NASH), a severe liver condition which affects a growing number of people around the world.
Our Commercialized Products
Making a difference through innovation
Theratechnologies makes a difference in the lives of patients through the development and commercialization of products addressing important unmet medical needs.